Daisuke Sugiyama

TL;DR: Depletion of FOXP3hi Treg cells from tumor tissues, which would augment antitumor immunity, could thus be used as an effective treatment strategy for CRCs and other cancers, whereas strategies that locally increase the population ofFOXP3lo non-Treg cells could be used to suppress or prevent tumor formation.

TL;DR: Cell-depleting anti-CCR4 mAb therapy is instrumental for evoking and enhancing tumor immunity in humans via selectively removing effector-type FOXP3+ Treg cells by selectively depleting eTreg cells.

TL;DR: FMT was safely performed in patients and might offer a novel therapeutic option for aGVHD and Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT.

TL;DR: It is shown that Treg cells can render self-reactive human CD8+ T cells anergic in vitro in vitro, likely by controlling the costimulatory function of antigen-presenting cells.

TL;DR: CD15s (sialyl Lewis x) was highly specific for activated, terminally differentiated, and most suppressive FoxP3high effector Treg (eTreg) cells and able to differentiate them in various clinical settings from nonsuppressive FOXP3+ T cells secreting inflammatory cytokines.